Currently holds positions in FibroGen Inc and Intra-Cellular Therapies Inc
Position | Company | Period |
---|---|---|
Independent Director | FibroGen Inc | Oct. 1, 1993 - |
Independent Director | Intra-Cellular Therapies Inc | Jan. 1, 2014 - |
Search
Notification date | Transaction date | B/S Transaction type |
Nb. shares Price Value |
Number of shares | Price | Total value | Details | |
---|---|---|---|---|---|---|---|---|
2023-12-14 | 2023-12-12 |
Calyxt Inc
(CLXT)
|
B Purchase |
517,107
+46.8%
10.585,470,992 USD |
517,107 +46.8% | 10.58 | 5,470,992 USD | |
2023-06-02 | 2023-06-01 |
Calyxt Inc
(CLXT)
|
B Purchase |
1,000
+0.1%
31.5031,500 USD |
1,000 +0.1% | 31.50 | 31,500 USD | |
2023-05-22 | 2023-05-22 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
1,750,000
-99.6%
32.8257,435,000 USD |
1,750,000 -99.6% | 32.82 | 57,435,000 USD | |
2023-03-30 | 2023-03-30 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
130,024
-8.2%
36.264,714,345 USD |
130,024 -8.2% | 36.26 | 4,714,345 USD | |
2023-03-30 | 2023-03-29 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
9,926
-0.6%
36.95366,766 USD |
9,926 -0.6% | 36.95 | 366,766 USD | |
2022-12-13 | 2022-12-09 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
19,990
-12.8%
42.07840,939 USD |
19,990 -12.8% | 42.07 | 840,939 USD | |
2022-11-21 | 2022-11-17 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
120,000
-43.4%
42.335,079,924 USD |
120,000 -43.4% | 42.33 | 5,079,924 USD | |
2022-09-15 | 2022-09-15 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
52,025
-15.8%
42.212,195,960 USD |
52,025 -15.8% | 42.21 | 2,195,960 USD | |
2022-09-15 | 2022-09-14 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
47,975
-12.7%
42.412,034,428 USD |
47,975 -12.7% | 42.41 | 2,034,428 USD | |
2022-08-11 | 2022-08-09 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
45,000
-10.7%
43.731,967,823 USD |
45,000 -10.7% | 43.73 | 1,967,823 USD | |
2022-05-23 | 2022-05-20 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
123,696
-21.5%
39.284,858,655 USD |
123,696 -21.5% | 39.28 | 4,858,655 USD | |
2022-05-23 | 2022-05-19 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
26,304
-4.4%
40.091,054,651 USD |
26,304 -4.4% | 40.09 | 1,054,651 USD | |
2022-03-30 | 2022-03-29 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
60,000
-9.1%
38.592,315,322 USD |
60,000 -9.1% | 38.59 | 2,315,322 USD | |
2022-03-21 | 2022-03-21 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
14,322
-100.0%
39.05559,288 USD |
14,322 -100.0% | 39.05 | 559,288 USD | |
2022-03-21 | 2022-03-21 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
25,545
-100.0%
39.05997,558 USD |
25,545 -100.0% | 39.05 | 997,558 USD | |
2022-03-21 | 2022-03-18 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
56,181
-39.7%
39.772,234,094 USD |
56,181 -39.7% | 39.77 | 2,234,094 USD | |
2022-03-21 | 2022-03-18 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
26,238
-64.7%
39.381,033,334 USD |
26,238 -64.7% | 39.38 | 1,033,334 USD | |
2022-03-21 | 2022-03-18 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
46,803
-64.7%
39.381,843,247 USD |
46,803 -64.7% | 39.38 | 1,843,247 USD | |
2022-03-18 | 2022-03-18 |
Intra-Cellular Therapies Inc
(ITCI)
|
S Sale |
15,736
-100.0%
61.35965,352 USD |
15,736 -100.0% | 61.35 | 965,352 USD | |
2022-03-18 | 2022-03-18 |
Intra-Cellular Therapies Inc
(ITCI)
|
S Sale |
4,901
-23.7%
60.63297,154 USD |
4,901 -23.7% | 60.63 | 297,154 USD | |
2022-03-18 | 2022-03-17 |
Intra-Cellular Therapies Inc
(ITCI)
|
S Sale |
114,912
-84.8%
60.416,941,570 USD |
114,912 -84.8% | 60.41 | 6,941,570 USD | |
2022-03-18 | 2022-03-17 |
Intra-Cellular Therapies Inc
(ITCI)
|
S Sale |
26,587
-16.4%
59.991,595,076 USD |
26,587 -16.4% | 59.99 | 1,595,076 USD | |
2022-03-18 | 2022-03-16 |
Intra-Cellular Therapies Inc
(ITCI)
|
S Sale |
43,848
-21.3%
59.532,610,057 USD |
43,848 -21.3% | 59.53 | 2,610,057 USD | |
2022-03-18 | 2022-03-16 |
Intra-Cellular Therapies Inc
(ITCI)
|
S Sale |
20,686
-9.1%
58.721,214,771 USD |
20,686 -9.1% | 58.72 | 1,214,771 USD | |
2021-11-18 | 2021-11-17 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
31,341
-2.7%
42.331,326,636 USD |
31,341 -2.7% | 42.33 | 1,326,636 USD | |
2021-11-18 | 2021-11-17 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
38,815
-2.1%
42.351,643,749 USD |
38,815 -2.1% | 42.35 | 1,643,749 USD | |
2021-11-18 | 2021-11-17 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
69,233
-12.2%
42.352,931,900 USD |
69,233 -12.2% | 42.35 | 2,931,900 USD | |
2021-11-18 | 2021-11-17 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
62,435
-9.1%
42.392,646,401 USD |
62,435 -9.1% | 42.39 | 2,646,401 USD | |
2021-11-18 | 2021-11-16 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
12,565
-1.8%
42.01527,805 USD |
12,565 -1.8% | 42.01 | 527,805 USD | |
2021-06-29 | 2021-06-29 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
479,800
-12.2%
41.2619,794,437 USD |
479,800 -12.2% | 41.26 | 19,794,437 USD | |
2021-06-29 | 2021-06-29 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
1,200
-0.0%
42.0150,409 USD |
1,200 -0.0% | 42.01 | 50,409 USD | |
2021-06-29 | 2021-06-28 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
167,448
-4.1%
42.117,051,269 USD |
167,448 -4.1% | 42.11 | 7,051,269 USD | |
2021-06-29 | 2021-06-25 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
487,364
-10.6%
42.6920,807,519 USD |
487,364 -10.6% | 42.69 | 20,807,519 USD | |
2021-06-29 | 2021-06-25 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
179,100
-16.1%
42.817,666,501 USD |
179,100 -16.1% | 42.81 | 7,666,501 USD | |
2020-10-22 | 2020-10-20 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
463,200
-100.0%
42.0019,454,400 USD |
463,200 -100.0% | 42.00 | 19,454,400 USD | |
2020-06-23 | 2020-06-18 |
Royalty Pharma PLC
(RPRX)
|
B Purchase |
15,000
+inf%
28.00420,000 USD |
15,000 +inf% | 28.00 | 420,000 USD | |
2022-12-13 | 2002-12-12 |
Royalty Pharma PLC
(RPRX)
|
S Sale |
40,010
-29.3%
41.981,679,684 USD |
40,010 -29.3% | 41.98 | 1,679,684 USD |